z-logo
Premium
Production of lentiviral vectors by large‐scale transient transfection of suspension cultures and affinity chromatography purification
Author(s) -
Segura María Mercedes,
Garnier Alain,
Durocher Yves,
Coelho Helene,
Kamen Amine
Publication year - 2007
Publication title -
biotechnology and bioengineering
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.136
H-Index - 189
eISSN - 1097-0290
pISSN - 0006-3592
DOI - 10.1002/bit.21467
Subject(s) - polyethylenimine , transfection , viral vector , bioreactor , affinity chromatography , cell culture , chromatography , chemistry , recombinant dna , biology , biochemistry , gene , enzyme , genetics , organic chemistry
The use of lentiviral vectors as gene delivery vehicles has become increasingly popular in recent years. The growing interest in these vectors has created a strong demand for large volumes of vector stocks, which entails the need for scaleable vector manufacturing procedures. In this work, we present a simple and robust process for the production of lentiviral vectors using scaleable production and purification methodologies. Lentivirus particles were produced by transient transfection of serum‐free suspension‐growing 293 EBNA‐1 cells with four plasmids encoding the vector components using linear polyethylenimine (PEI) as transfection reagent. This process was successfully scaled‐up from shake flaks to a 3‐L bioreactor from which 10 10 IVP were recovered. In addition, an affinity chromatography protocol designed for purification of bioactive oncoretroviral vectors has been adapted in this work for the purification of VSV‐G pseudotyped lentiviral vectors. Using heparin affinity chromatography, lentiviral particles were concentrated and purified directly from the clarified supernatants. During this step, a recovery of 53% of infective lentiviral particles was achieved while removing 94% of the impurities contained in the supernatant. Biotechnol. Bioeng. 2007; 98: 789–799. © 2007 Wiley Periodicals, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here